

Supplemental File 13: References 31-70

31. Vuoristo M, Farkkila M, Karvonen AL, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. *Gastroenterology* 1995;**108**(5):1470-8
32. Olsson R, Broome U, Danielsson A, et al. Colchicine treatment of primary sclerosing cholangitis. *Gastroenterology* 1995;**108**(4):1199-203
33. Lin DY, Sheen IS, Chu CM, Liaw YF. A prospective randomized trial of colchicine in prevention of liver cirrhosis in chronic hepatitis B patients. *Alimentary pharmacology & therapeutics* 1996;**10**(6):961-6
34. Poupon RE, Huet PM, Poupon R, Bonnand AM, Nhieu JT, Zafrani ES. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group. *Hepatology* 1996;**24**(5):1098-103 doi: 10.1002/hep.510240520[published Online First: Epub Date]].
35. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. *The New England journal of medicine* 1997;**336**(17):1202-7 doi: 10.1056/NEJM199704243361702[published Online First: Epub Date]].
36. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. *American journal of respiratory and critical care medicine* 1998;**158**(1):220-5 doi: 10.1164/ajrccm.158.1.9709089[published Online First: Epub Date]].
37. Colman J, Cromie S, Cox J, Roberts S, Dudley E, Dudley F. The natural history of alcoholic cirrhosis: Effect of colchicine [abstract]. *Hepatology (Baltimore, Md.)* 1998;**28**(Suppl 4):510a
38. Adhami JE, Basho J. Treatment with colchicine and survival of patients with ascitic cirrhosis: a double-blind randomized trial. *Panminerva medica* 1998;**40**(1):75-81
39. Almasio PL, Floreani A, Chiamonte M, et al. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. *Alimentary pharmacology & therapeutics* 2000;**14**(12):1645-52
40. Cortez-Pinto H, Alexandrino P, Camilo ME, et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. *European journal of gastroenterology & hepatology* 2002;**14**(4):377-81
41. Afdhal NH, Levine R, Brown R, Jr., Freilich B, O'Brien M, Brass C. Colchicine versus peg-interferon alfa 2b long term therapy: results of the 4 year copilot trial. *Journal of Hepatology* 2008;**48**:S4 doi: 10.1016/s0168-8278(08)60005-7[published Online First: Epub Date]].
42. Kaplan MM, Schmid C, Provenzale D, Sharma A, Dickstein G, McKusick A. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. *Gastroenterology* 1999;**117**(5):1173-80
43. Morgan TR, Weiss DG, Nemchausky B, et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. *Gastroenterology* 2005;**128**(4):882-90
44. Antoniou KM, Nicholson AG, Dimadi M, et al. Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. *The European respiratory journal* 2006;**28**(3):496-504 doi: 10.1183/09031936.06.00032605[published Online First: Epub Date]].

45. Muntoni S, Rojkind M, Muntoni S. Colchicine reduces procollagen III and increases pseudocholinesterase in chronic liver disease. *World journal of gastroenterology : WJG* 2010;**16**(23):2889-94
46. Ikeda T, Tozuka S, Noguchi O, et al. Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study. *J Hepatol* 1996;**24**(1):88-94
47. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. *Lancet* 2014;**383**(9936):2232-7 doi: 10.1016/S0140-6736(13)62709-9[published Online First: Epub Date]].
48. Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. *Archives of internal medicine* 2005;**165**(17):1987-91 doi: 10.1001/archinte.165.17.1987[published Online First: Epub Date]].
49. Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. *Annals of internal medicine* 2011;**155**(7):409-14 doi: 10.7326/0003-4819-155-7-201110040-00359[published Online First: Epub Date]].
50. Lukina G. Treatment of renal reactive amyloidosis (ReAm) in rheumatic diseases with dimethyl sulfoxide (DMSO) and colchicine (Col). *Zeitschrift fur Rheumatologie* 1995;**54**(5):377
51. Nikolaidis N, Kountouras J, Giouleme O, et al. Colchicine treatment of liver fibrosis. *Hepato-gastroenterology* 2006;**53**(68):281-5
52. Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. *Arthritis and rheumatism* 1974;**17**(5):609-14
53. Controlled study on the effects of a combined ursodeoxycholic acid plus colchicine treatment in primary biliary cirrhosis. Bile acids and the hepatobiliary system. From basic science to clinical practice. Proceedings of Falk Symposium 68th 1992 October 12-14, 1992; Basel, Switzerland.
54. van Echteld I, Wechalekar MD, Schlesinger N, Buchbinder R, Aletaha D. Colchicine for acute gout. *The Cochrane database of systematic reviews* 2014;**8**:CD006190 doi: 10.1002/14651858.CD006190.pub2[published Online First: Epub Date]].
55. Alabed S, Cabello JB, Irving GJ, Qintar M, Burls A. Colchicine for pericarditis. *The Cochrane database of systematic reviews* 2014;**8**:CD010652 doi: 10.1002/14651858.CD010652.pub2[published Online First: Epub Date]].
56. Wu B, Xu T, Li Y, Yin X. Interventions for reducing inflammation in familial Mediterranean fever. *The Cochrane database of systematic reviews* 2015;**3**:CD010893 doi: 10.1002/14651858.CD010893.pub2[published Online First: Epub Date]].
57. Raval J, Nagaraja V, Eslick GD, Denniss AR. The Role of Colchicine in Pericarditis - A Systematic Review and Meta-analysis of Randomised Trials. *Heart, lung & circulation* 2015 doi: 10.1016/j.hlc.2015.01.010[published Online First: Epub Date]].
58. Imazio M, Brucato A, Belli R, et al. Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014 - systematic review and meta-analysis. *Journal of cardiovascular medicine (Hagerstown, Md.)* 2014;**15**(12):840-6 doi: 10.2459/jcm.000000000000103[published Online First: Epub Date]].
59. Imazio M, Brucato A, Forno D, et al. Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis. *Heart* 2012;**98**(14):1078-82 doi: 10.1136/heartjnl-2011-301306[published Online First: Epub Date]].

60. Trivedi C, Sadadia M. Colchicine in prevention of atrial fibrillation following cardiac surgery: systematic review and meta-analysis. *Indian journal of pharmacology* 2014;**46**(6):590-5 doi: 10.4103/0253-7613.144905[published Online First: Epub Date]].
61. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. *The Cochrane database of systematic reviews* 2005(2):CD002148 doi: 10.1002/14651858.CD002148.pub2[published Online First: Epub Date]].
62. Gong Y, Gluud C. Colchicine for primary biliary cirrhosis. *The Cochrane database of systematic reviews* 2004(2):Cd004481 doi: 10.1002/14651858.CD004481.pub2[published Online First: Epub Date]].
63. Ioannidis JP, Karassa FB. The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence. *Bmj* 2010;**341**:c4875 doi: 10.1136/bmj.c4875[published Online First: Epub Date]].
64. Zorzela L, Golder S, Liu Y, et al. Quality of reporting in systematic reviews of adverse events: systematic review. *Bmj* 2014;**348**:f7668 doi: 10.1136/bmj.f7668[published Online First: Epub Date]].
65. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. *Archives of internal medicine* 2009;**169**(19):1756-61 doi: 10.1001/archinternmed.2009.306[published Online First: Epub Date]].
66. COLPET Protocol. A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Colchicine on Vascular Inflammation as Assessed With Position Emission Tomography (PET) Imaging in Patients With Atherosclerotic Vascular Disease (COLPET). Secondary A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Colchicine on Vascular Inflammation as Assessed With Position Emission Tomography (PET) Imaging in Patients With Atherosclerotic Vascular Disease (COLPET) NCT02162303. <https://clinicaltrials.gov/ct2/show/NCT02162303>
67. COACS Protocol. Colchicine for Acute Coronary Syndromes. A Multicenter Double Blind Randomized Trial. Secondary Colchicine for Acute Coronary Syndromes. A Multicenter Double Blind Randomized Trial NCT01906749. <https://clinicaltrials.gov/ct2/show/NCT01906749>.
68. LoDoCo2 Protocol. "The LoDoCo2 Trial": Low Dose Colchicine for secondary prevention of cardiovascular disease. Secondary "The LoDoCo2 Trial": Low Dose Colchicine for secondary prevention of cardiovascular disease ACTRN12614000093684. <https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12614000093684>.
69. Parise ER, Chehter L, Nogueira MD, et al. [Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. *Revista Da Associacao Medica Brasileira* 1995;**41**(3):207-12
70. Verma S, Eikelboom JW, Nidorf SM, et al. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. *BMC Cardiovasc Disord* 2015;**15**:96 doi: 10.1186/s12872-015-0068-3[published Online First: Epub Date]].